More than 1,500 executives attending the opening plenary session of BIO-Europe 2008 today took a moment to pay special tribute to the man who made it all possible, Alfred Mueller, the former Chairman of the Life Science Practices at Ernst & Young International.
Mueller, who passed away recently, is widely considered the founding father of what Read more »
The deal Osiris Therapeutics has just signed with Genzyme was made possible by a bold move the stem cell specialist took earlier this year, when it sold its only marketed product, Osteocel, for USD 85 million.
While the sale of its only source of revenue might have at the time seemed risky, particularly as it resulted Read more »
The stock market’s treatment of U.S. cancer drug developer ArQule this week illustrates just how tough life has become for small, high risk life science companies, with investors seemingly completely unwilling, or maybe unable, to justify owning shares in these types of investments.
On Monday, the company announced two licensing deals with Daiichi Sankyo netting USD Read more »
The recent election holds great promise for the biotech industry—from health care to energy to climate change to environmental sustainability—and the USA are ready to realize the vast potential of our burgeoning innovation economy.
By Jim Greenwood
President and CEO of BIO
President-elect Obama led an inspiring campaign and secured a convincing victory. So many of us Read more »
Big Pharma is to biotech what Big Government is to Wall Street.
Well, perhaps not so much, as one relationship is a mutually beneficial investment, while the other is a pocket-draining donation; one benefactor is using its own money, while the other is already the world’s biggest debtor … I’ll stop there, but the point Read more »
Harnessing Biological Systems to Generate Novel Antibiotics and Offer a Service Business to Grow Revenues
After five years developing novel agents for hospital-based infections, Novacta Biosystems is now aggressively developing new business opportunities and arrives at BIO-Europe 2008 actively scouting for partners.
Having recently won financing and validation of its science from the Wellcome Trust, Novacta earlier Read more »
Novel Peptidomimetics Target Occular Diseases
Bringing a novel approach to treating occular diseases, Garth Cumberlidge, the President and CEO of Mimetogen Pharmaceuticals Inc. has set his sights on partnering at BIO-Europe 2008 to advance into clinical trials small molecules to treat dry eye and glaucoma.
The potential is rich with the market for the dry eye indication Read more »
On the minds of executives in the biotech industry is the current financial crisis and its effects on innovation and business. Featured speakers at BIO-Europe 2008, share their insights with FierceBioResearcher on how to keep the wheels of innovation turning in a world gripped by financial turbulence.
Bill Ringo, keynote panelist and Senior VP of Strategy Read more »
Newsletter